Investing.com - Aytu BioScience (NASDAQ:AYTU) reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Aytu BioScience announced earnings per share of $-0.490 on revenue of $27.45M. Analysts polled by Investing.com anticipated EPS of $-0.370 on revenue of $25.5M.
Aytu BioScience shares are down 53.76% from the beginning of the year, still down 93.79% from its 52 week high of $3.06 set on September 28, 2021.
Aytu BioScience follows other major Healthcare sector earnings this month
Aytu BioScience's report follows an earnings beat by Merck ADR on September 9, who reported EPS of $0.5392 on revenue of $5.69B, compared to forecasts EPS of $0.5165 on revenue of $5.57B.
Veeva Systems A had beat expectations on August 31 with second quarter EPS of $1.03 on revenue of $534.22M, compared to forecast for EPS of $1.01 on revenue of $530.71M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar